文献速递血液净化与透析慢性肾脏病

罗沙司他治疗透析初治肾衰竭患者贫血的汇总分析

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.
PubMed 文献 · Kidney Int Rep · 2020-12-24

该汇总分析纳入3项3期随机开放标签活性对照试验,比较罗沙司他与阿法依泊汀在透析初治(起始透析2周至≤4个月)肾衰竭患者中的疗效与心血管安全性。结果显示罗沙司他升高血红蛋白非劣于阿法依泊汀,且MACE和MACE+风险更低。

要点

  • 罗沙司他组第28至52周血红蛋白平均变化较阿法依泊汀组高0.22 g/dl(95%CI 0.05-0.40,P=0.0130)。
  • 罗沙司他组MACE风险低于阿法依泊汀组(HR 0.70,95%CI 0.51-0.96)。
  • 罗沙司他组MACE+风险也低于阿法依泊汀组(HR 0.66,95%CI 0.50-0.89)。

核心结论

  • 罗沙司他在透析初治肾衰竭患者中纠正贫血的疗效至少不劣于阿法依泊汀,且MACE和MACE+风险更低。

研究设计与样本

  • 汇总3项3期随机开放标签活性对照试验,纳入1530例透析初治(起始透析2周至≤4个月)肾衰竭成人患者,随机接受罗沙司他或阿法依泊汀。

主要发现

  • 第28至52周血红蛋白平均变化(不考虑挽救治疗)罗沙司他组为2.12(1.45)g/dl,阿法依泊汀组为1.91(1.42)g/dl,最小二乘均值差0.22(95%CI 0.05-0.40,P=0.0130)。
  • 罗沙司他组MACE风险低于阿法依泊汀组(HR 0.70,95%CI 0.51-0.96),MACE+风险也低于阿法依泊汀组(HR 0.66,95%CI 0.50-0.89)。
  • 全因死亡风险两组差异无统计学意义(HR 0.76,95%CI 0.52-1.11)。

临床怎么用

  • 对于透析初治的肾衰竭贫血患者,罗沙司他可作为阿法依泊汀的替代选择,且可能降低心血管复合终点风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Erythropoiesis-stimulating agents are associated with increased cardiovascular risk when higher doses are used toward higher hematocrit targets. Patients new to dialysis are at higher risk for morbidity and mortality. Systematic evaluation of this population was predefined in the roxadustat clinical development program. Roxadustat is a hypoxia-inducible prolyl hydroxylase inhibitor. METHODS: Data were pooled from 3 phase 3, randomized, open-label, active-controlled trials. Eligible adults had kidney failure and initiated dialysis for 2 weeks to ≤ 4 months prior to randomization to roxadustat or epoetin alfa. Efficacy was assessed as mean change in hemoglobin from baseline averaged over weeks 28 to 52, regardless of rescue therapy. Key cardiovascular safety endpoints were major adverse cardiovascular events (MACE; all-cause mortality [ACM], myocardial infarction, and stroke), and MACE+ (MACE plus unstable angina or congestive heart failure requiring hospitalization), and ACM. RESULTS: This study included 1530 patients with kidney failure incident to dialysis. Mean (SD) changes in hemoglobin from baseline averaged over weeks 28 to 52, regardless of rescue therapy, were 2.12 (1.45) versus 1.91 (1.42) g/dl in the roxadustat and epoetin alfa groups (least-squares mean difference: 0.22; 95% CI, 0.05 to 0.40; P = 0.0130). Risks of MACE and MACE+ were lower in the roxadustat group (hazard ratio [HR], 0.70; 95% CI, 0.51 to 0.96) than the epoetin alfa group (HR, 0.66; 95% CI, 0.50 to 0.89); the HR for ACM was 0.76 (95% CI, 0.52 to 1.11). CONCLUSION: Roxadustat was at least as efficacious as epoetin alfa. Roxadustat had a lower risk of MACE/MACE+ in patients new to dialysis.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Provenzano R, Fishbane S, Szczech L, et al. Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis. Kidney Int Rep. 2020. PMID: 33732976. doi:10.1016/j.ekir.2020.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。